amiridine and Disease-Models--Animal

Traumatic neuropathies are among the most actual problems in neurology due to the severe neurological deficit in most cases and poor prognosis of recovery. We evaluated the effect of ipidacrin (cholinesterase inhibitor) and magnetic stimulation on neuroplastic axonal changes after experimental neurotmesis of rat's sciatic nerve.. Animals (20 rats) were stratified into 3 groups. There was no treatment in the control group; in the second -group experimental animals underwent 3-5 min daily rhythmic magnetic stimulation (0,8-1T, 3 Hz) The third group of animals received intramuscular 0,035 mg of ipidacrin daily within 1 month.. Based on the received data on the restoration of myelin, axons, myelin nodes structure and lemmocyte ultrastructure), we have concluded that both magnetic stimulation and ipidacrin can trigger restorative and compensative processes in traumatic neuropathies.

Topics: Aminoquinolines; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Magnetic Field Therapy; Male; Neuronal Plasticity; Rats; Rats, Inbred Strains; Sciatic Nerve; Sciatic Neuropathy

Compression-ischemic neuropathies remain one of the most actual problems of contemporary neurology due to the prevalence and commonly poor outcome. In the present work, we studied pathogenetic mechanisms of the formation and restoration of neural conductivity in the compression-ischemic model in rabbits and analyzed some features of therapeutic efficacy of the anticholinesterase drug neuromidin in clinical treatment of compression-ischemic neuropathies. We observed a generalized reaction of the nervous system to the acute limb compression in experimental animals. The ability of neuromidin to improve the central conductivity has been clearly shown. The results obtained allow recommending neuromidin in the treatment of patients with compression-ischemic neuropathies owing to its central and peripheral effects.

Topics: Aminoquinolines; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Ischemia; Male; Nerve Compression Syndromes; Neural Conduction; Peripheral Nervous System Diseases; Rabbits

Topics: Aminoquinolines; Animals; Biogenic Monoamines; Cholinesterase Inhibitors; Disease Models, Animal; Male; Memory Disorders; Neurotransmitter Agents; Nootropic Agents; Rats; Scopolamine; Tacrine

Development of behavioral disturbances was investigated during N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration (0,2 mg/kg, i/m, at 48 h. intervals, total dose 11.2-13.2 mg/kg) in experiments on two monkeys Macaca rhesus. MPTP induced the complex of symptoms, which are typical for idiopathic Parkinson's disease. Administration of amiridine (0,25-0,4 mg/kg) to MPTP-treated monkeys caused gradual decline of Parkinson syndrome. Mechanisms of action of amiridine are discussed.

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Behavior, Animal; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Macaca mulatta; Male; Parkinson Disease, Secondary; Psychotropic Drugs; Time Factors